NO20053167L - Krystallinsk form. - Google Patents

Krystallinsk form.

Info

Publication number
NO20053167L
NO20053167L NO20053167A NO20053167A NO20053167L NO 20053167 L NO20053167 L NO 20053167L NO 20053167 A NO20053167 A NO 20053167A NO 20053167 A NO20053167 A NO 20053167A NO 20053167 L NO20053167 L NO 20053167L
Authority
NO
Norway
Prior art keywords
crystalline form
ethenesulfonamide
chlorothien
oxopyrrolidine
oxoethyl
Prior art date
Application number
NO20053167A
Other languages
English (en)
Inventor
Gita Punjabhai Shah
Robert John Young
Henry Anderson Kelly
Nigel Stephen Watson
Orco Philip C Dell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20053167L publication Critical patent/NO20053167L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

(E)-2-(5-Klortien-2-yl)-N-{(3S)-l-[(lS)-l-metyl-2-morfolin-4-yl-2-oksoetyl]-2- oksopyrrohdin-3-yl}etensulfonamid i i det vesentlige krystallinsk form, farmasøytiske formuleringer derav, fremgangsmåter for fremstilling av det og dets anvendelse innen medisin, særlig anvendelse ved å lindre en klinisk tilstand for hvilken en Faktor Xa inhibitor er indikert.
NO20053167A 2002-12-06 2005-06-28 Krystallinsk form. NO20053167L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228533.6A GB0228533D0 (en) 2002-12-06 2002-12-06 Crystalline form
PCT/EP2003/013800 WO2004052878A2 (en) 2002-12-06 2003-12-04 Crystalline derivative of 2- (5-chlorothien-2-yl)-n- ((3s)-1((1s)-1-methyl-2-morpholin-4-yl)-2-oxoethyl)-2-oxopyrrolidin-3-yl) ethensulfonamide

Publications (1)

Publication Number Publication Date
NO20053167L true NO20053167L (no) 2005-06-28

Family

ID=9949229

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053167A NO20053167L (no) 2002-12-06 2005-06-28 Krystallinsk form.

Country Status (28)

Country Link
US (1) US7645338B2 (no)
EP (1) EP1567519B1 (no)
JP (1) JP4660197B2 (no)
KR (1) KR20050085328A (no)
CN (1) CN100378098C (no)
AR (1) AR042304A1 (no)
AT (1) ATE373652T1 (no)
AU (1) AU2003293779B2 (no)
BR (1) BR0317067A (no)
CA (1) CA2508699A1 (no)
CY (1) CY1107011T1 (no)
DE (1) DE60316467T2 (no)
DK (1) DK1567519T3 (no)
ES (1) ES2290541T3 (no)
GB (1) GB0228533D0 (no)
HK (1) HK1083491A1 (no)
IS (1) IS7927A (no)
MA (1) MA27574A1 (no)
MX (1) MXPA05006032A (no)
MY (1) MY139916A (no)
NO (1) NO20053167L (no)
NZ (1) NZ540365A (no)
PL (1) PL377184A1 (no)
PT (1) PT1567519E (no)
RU (1) RU2339634C2 (no)
TW (1) TW200420560A (no)
WO (1) WO2004052878A2 (no)
ZA (1) ZA200504384B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268281A1 (en) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
US6281227B1 (en) * 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
US6602864B1 (en) * 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
AU2001255408A1 (en) * 2000-04-14 2001-10-30 Corvas International, Inc. Tetrahydro-azepinone derivatives as thrombin inhibitors
WO2002010830A2 (en) * 2000-07-27 2002-02-07 Zetetic Institute Multiple-source arrays for confocal and near-field microscopy
AU2001280979A1 (en) * 2000-08-02 2002-02-13 Captivads, Inc. Interactive advertising and multi-media system with a plurality of mobile platforms
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0127568D0 (en) * 2001-11-16 2002-01-09 Glaxo Group Ltd Chemical compounds
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AU2003293779A1 (en) 2004-06-30
AR042304A1 (es) 2005-06-15
BR0317067A (pt) 2005-10-25
MXPA05006032A (es) 2005-08-18
PL377184A1 (pl) 2006-01-23
MA27574A1 (fr) 2005-10-03
TW200420560A (en) 2004-10-16
DE60316467D1 (en) 2007-10-31
CY1107011T1 (el) 2012-09-26
RU2005121262A (ru) 2006-01-20
EP1567519B1 (en) 2007-09-19
MY139916A (en) 2009-11-30
CA2508699A1 (en) 2004-06-24
DK1567519T3 (da) 2008-01-28
CN1745079A (zh) 2006-03-08
KR20050085328A (ko) 2005-08-29
WO2004052878A3 (en) 2004-08-12
CN100378098C (zh) 2008-04-02
US7645338B2 (en) 2010-01-12
JP2006510648A (ja) 2006-03-30
HK1083491A1 (en) 2006-07-07
GB0228533D0 (en) 2003-01-15
ES2290541T3 (es) 2008-02-16
DE60316467T2 (de) 2008-06-12
AU2003293779B2 (en) 2008-01-31
ZA200504384B (en) 2006-03-29
WO2004052878A2 (en) 2004-06-24
RU2339634C2 (ru) 2008-11-27
NZ540365A (en) 2008-01-31
ATE373652T1 (de) 2007-10-15
JP4660197B2 (ja) 2011-03-30
US20060124049A1 (en) 2006-06-15
PT1567519E (pt) 2007-12-17
EP1567519A2 (en) 2005-08-31
IS7927A (is) 2005-07-01

Similar Documents

Publication Publication Date Title
NL300994I2 (nl) Apremilast of een farmaceutisch aanvaardbaar zout daarvan
UA84146C2 (ru) Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
MX2010004501A (es) Inhibidor de la proteina de activacion de 5-lipoxigenasa (plap).
HK1100559A1 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
MXPA05001712A (es) Bifenilcarboxamidas sustituidas con n-aril piperidina como inhibidores de la secrecion de apolipoproteina b.
MX2010007426A (es) Composiciones farmaceuticas para tratar trastorno del higado graso.
Pakhare et al. Piezosurgery®-assisted periodontally accelerated osteogenic orthodontics
NO20053167L (no) Krystallinsk form.
CY1108238T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
MY138698A (en) Method for synthesis of (2s)-indoline-2-carboxylic acid, and use in the synthesis of perindopril
ATE402144T1 (de) Pyrrolidin-2-on-derivate als inhibitoren von thrombin und faktor xa
TNSN07166A1 (en) Composition comprising vlp and amyloid-beta peptide
ITMI20011321A0 (it) Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del
GEP20084343B (en) Use of indole derivatives for the treatment of neuropathic pain
JP2008505075A5 (no)
WO2007085933A3 (en) Process for the preparation of n-[1-(s)-ethoxycarbonyl-1-butyl]-(s)-alanine-dmt complex and its use in the preparation of perindopril
CL2007003574A1 (es) 4-((1r,3r)-1-(3,5-difluorofenil)-3-(4-(3-etil-5-isopropil-4h-1,2,4-triazol-4-il)piperidin-1-il)butil)-1-(metilsulfonil)piperidina; su proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso en el tratamiento de una
MY137288A (en) New process for the synthesis of n-[(s)-1-ethoxycarbonylbutyl]-(s)-alanine and application in the synthesis of perindopril
MY137391A (en) New process for the synthesis of n-[(s)-1-ethoxycarbonylbutyl]-(s)-alanine and application in the synthesis of perindopril
AU2003296482A1 (en) Tetracyclines as anti-fungal agents for treatment of ringworm
AU2002950887A0 (en) Orally deliverable pharmaceutical composition containing protein pump inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application